Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast TumorsDonald Küfe, Jeffrey Schlom, Giorgio Inghirami et al.|Hybridoma|1984Cited by 580
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C. Townsend, Michelle A. Kelliher, Mark A. Murakami et al.|Cancer Cell|2016Cited by 304
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumorsRoberto Chiarle, Giorgio Inghirami|Blood|2003Cited by 247
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genesRoberto Piva, Giorgio Inghirami|Journal of Clinical Investigation|2006Cited by 164
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Michael R. Green, Saber Tadros et al.|Cancer Discovery|2020Cited by 159